II. Precautions
- Cardiovascular disease risk with Androgen Replacement is still unclear
- Androgen Replacement is not recommended for asymptomatic men or those with normal range Serum Testosterone
- Discontinue Testosterone Supplementation if no improvement after 3-6 months
- Androgen Replacement may be abused as an Anabolic Aid in sports
- Consider completing a Controlled Substance Contract
III. Indications: Men
- Depression, Fatigue, Muscle wasting in HIV or AIDS
- Symptomatic Testicular Failure AND low morning Serum Testosterone levels<300 ng/dl (two levels are recommended)
- See Male Menopause
- See Hypogonadism
- FDA approved for low Testosterone due to underlying cause (e.g. pituitary disorder, testicular infection)
- Not FDA approved for normal Testosterone decline with routine aging
- Symptoms
- Decreased libido
- Erectile Dysfunction (PDE5 Inhibitors are preferred as first-line)
IV. Contraindications
- Absolute Contraindications
- Breast Cancer
- Polycythemia Vera (Hematocrit >54%)
- Prostate Cancer or suspicion for active Prostate Cancer (e.g. PSA > 4 mcg/L, ProstateNodules)
- Cardiovascular event (CVA or MI) in the last 6 months
- Relative Contraindications
- Normal Serum Testosterone
- Hematocrit >48% (prior to starting Testosterone Replacement)
- Fertility desired (Testosterone Replacement decreases spermatogenesis)
- Untreated Obstructive Sleep Apnea
- Uncontrolled Congestive Heart Failure
V. Efficacy
- Positive
- Increases bone density or decreases bone loss (Lumbar Spine, hip)
- Increase Lean Body Mass and Muscle Strength
- Decrease body fat
- Increase serum Hematocrit
- Increases sense of well-being, mood (variable effects)
- Increases libido
- Disproved
- Does not improve cognition (with or without Dementia)
VI. Adverse Effects: Cardiovascular (mixed results)
- Cardiovascular Disease Risk
- Increased mortality, CVA and MI may be associated with Testosterone Replacement
- Intramuscular Testosterone may be associated with higher Cardiovascular Risk than transdermal
- Vigen (2013) JAMA 310(17):1829-36 [PubMed]
- One large VA study showed decreased cardiovascular mortality (but has not been replicated by other studies)
- Transdermal Testosterone Gel (Androgel) does not appear to effect cardiovascular event risk
- However, there was an increased risk of Atrial Fibrillation (as well as Pulmonary Embolism and Acute Kidney Injury)
- Lincoff (2023) N Engl J Med 389(2):107-17 +PMID: 37326322 [PubMed]
- Older studies suggested no increased cardiovascular disease risk
- Increased mortality, CVA and MI may be associated with Testosterone Replacement
-
Venous Thromboembolism
- Increased risk with Testosterone Replacement
- Study shows increased risk for those with Thrombophilia
- Study shows no increased risk with men without other risk factors
VII. Adverse Effects: General (decreased risk if Testosterone Level stable)
- HDL Cholesterol declines
- May exacerbate Sleep Apnea
- Hepatotoxicity (especially oral preparations)
- Virilization (Hirsutism, Alopecia, Acne)
- Lethargy (low Serum Testosterone fluctuations)
- Edema
- Gynecomastia
- Behavior and mood changes
- Moodiness or irritability
- Aggressive behavior
- Increased Prostate Cancer growth (disproved)
- Erythropoesis stimulation related effects
- Polycythemia, Thromboembolism and cerebral vascular accident risk
VIII. Labs: Monitoring while on Testosterone
- See Androgen Replacement in Women for monitoring women
- Baseline Labs
- See Male Hypogonadism
- Morning Serum Testosterone level
- Confirm low Testosterone (<300 ng/dl) on 2 different morning Serum Testosterone levels
- Consider Free Testosterone and Sex Hormone Binding Globulin (SHBG)
- Prostate Specific Antigen (PSA)
- Obtain Prostate Specific Antigen (PSA) in age >=40 years old
- Avoid starting Testosterone replacment if PSA abnormal (e.g. >4 ng/ml)
- Digital Rectal Exam and Prostate examination
- Complete Blood Count (or Hematocrit)
- Baseline Hematocrit >48% is a contraindication for starting Testosterone Replacement
- Liver Function Tests (if using oral Testosterone, which is not recommended)
- Monitoring for non-injectable preparations
- History and exam
- Follow-up at 3-6 months after initiation of therapy, and then annually if stable
- Total Serum Testosterone
- Obtain 3-6 months after starting therapy, then annually if stable
- Goal total Serum Testosterone level to mid-normal range 400 to 700 ng/dl AND Improved symptoms
- Complete Blood Count
- Obtain 3-6 months after starting therapy, then annually if stable
- Stop Androgen Replacement if Hematocrit >54%
- Prostate Specific Antigen (PSA) and Digital Rectal Exam (DRE)
- Indicated if older than age 40 years and baseline PSA >0.6 ng/ml
- Obtain PSA, DRE baseline and 3-6 months after initiation of therapy
- Refer to urology if >1.4 ng/ml increase within 12 months or Prostate nodularity
- Bone Mineral Density
- Indicated in men with Osteoporosis or low mechanism Fracture
- Obtain at 1-2 years after initiation of therapy
- Liver Function Tests
- If using oral Testosterone (which, again, is not recommended)
- History and exam
- Monitoring for Establishing Injection Dose
- Serum Testosterone at one week post injection
- Level above normal: decrease subsequent doses
- Serum Testosterone at two weeks post injection
- Level below normal: increase injection frequency
- Serum Testosterone at one week post injection
IX. Dosing: Testosterone Injection (Intramuscular)
- Transdermal delivery is preferred over intramuscular
- Cardiovascular Risks may be higher with injectable
- Medications: Every 2 weeks
- Testosterone cypionate (Depo-Testosterone)
- Start 50 to 100 mg every 2 weeks (may increase up to 200 to a maximum of 400 mg)
- Testosterone enanthate (Delatestryl)
- Start 50 to 100 mg every 2 weeks (may increase up to 200 to a maximum of 400 mg)
- Testosterone Propionate
- Start 10 to 25 mg every 3 weeks
- Testosterone cypionate (Depo-Testosterone)
- Medications: Every 10 weeks
- Testosterone undecanoate (Aveed) injectable
- Dose: 3-mL (750 mg) Intramuscular Injection
- Give once at starting protocol THEN
- Give again in 4 weeks THEN
- Give every 10 weeks
- Adverse effects
- Pulmonary-Oil Microembolism (POME) and Anaphylaxis
- Precautions
- Carries black box warning (regarding POME, Anaphylaxis) and certification for prescribers
X. Dosing: Testosterone Transdermal (preferred, physiologic)
- Background
- Serum Testosterone peaks 2 hours post-patch application
- Risk of skin-to-skin transmission of Testosterone
-
Testosterone
Patch (Testoderm)
- Dose: One 4 or 6 mg patch
- Apply to shaved Scrotum every 24 hours
- Much less irritating than Androderm
- Transdermal Testosterone Solution (Axiron)
- Dose: 60 mg daily (30 to 120 mg daily)
- Apply to axillary area (similar to deodorant)
- Risk for transfer to others
- Androderm ($98 per month)
- Transdermal Gels
- Dosing: Equivalent to 50-100 mg daily
- Formulations
- Testim 1%
- Fortesta
- Androgel (Testosterone 1% gel) four pumps (5 grams) topically daily
- Androgel (Testosterone 1.62% gel) two pumps topically daily
XI. Dosing: Other forms
-
Testosterone buccal (Striant) 30 mg to gums twice daily
- May cause oral irritation
- New option less studied than other forms
-
Testosterone implanted pellets (Testopel)
- Dose: 150 to 450 mg (up to 600 to 900 mg) implanted SQ every 3-6 months
- Used for Delayed Puberty in males
-
Testosterone intranasal gel (Natesto)
- Dose: One actuation (33 mg) in each nostril three times daily
- Oral Testosterone (not recommended)
- Listed for completeness
- Not recommended due to hepatotoxicity and less effect
- Agents
- Methyltestosterone (Android)
- Fluoxymesterone (Halotestin)
XII. References
- (2015) Presc Lett 22(10):56
- Bhasin (2010) J Clin Endocrinol Metab 95(6): 2536-59 [PubMed]
- Dewire (1996) Am Fam Physician 53(6):2101-6 [PubMed]
- Heidelbaugh (2024) Am Fam Physician 109(6): 543-9 [PubMed]
- Margo (2006) Am Fam Physician 73(9):1591-603 [PubMed]
- Petering (2017) Am Fam Physician 96(7): 441-9 [PubMed]
- Schow (1997) Postgrad Med 101(3): 62-79 [PubMed]
- Tan (1998) Postgrad Med 103(5): 247-56 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
androderm (on 11/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ANDRODERM 2 MG/24HR PATCH | $9.82 each | |
ANDRODERM 4 MG/24HR PATCH | $19.69 each | |
testim (on 4/20/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TESTIM 1% (50 MG) GEL | Generic | $0.95 per gram |
androgel (on 2/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ANDROGEL 1.62% GEL PUMP | Generic | $0.49 per gram |